Feldman Steven R, Koo John Y M, Menter Alan, Bagel Jerry
Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1071, USA.
J Am Acad Dermatol. 2005 Jul;53(1):101-7. doi: 10.1016/j.jaad.2005.03.050.
Psoriasis has a tremendous effect on health-related quality of life. Phototherapy and systemic treatments are used for patients with more debilitating (physically and emotionally) forms of the disease. These treatments can be extremely effective but can also have potentially significant adverse effects. The decision to undertake systemic treatment of psoriasis is a complex one that requires both experience and judgment. With the recent advent of new biologic systemic drugs for moderate to severe psoriasis, the need to clarify patient candidates for systemic therapy has become very important. Here, we present a diagnostic algorithm and a formal measure, the Koo-Menter Psoriasis Instrument (KMPI), to aid in identifying patients that would benefit from systemic therapy. In addition, the KMPI can be used to document and justify treatment decisions for health care payers. While the decision to undertake systemic treatment and the choice of specific treatment plan must ultimately be made mutually by the patient and physician, these tools are designed to provide information that will be valuable in these determinations.
银屑病对健康相关生活质量有巨大影响。光疗和全身治疗用于患有更使人衰弱（身体和情绪方面）的该疾病形式的患者。这些治疗可能极其有效，但也可能有潜在的重大不良反应。决定对银屑病进行全身治疗是一个复杂的过程，需要经验和判断力。随着用于中度至重度银屑病的新型生物全身药物的近期出现，明确全身治疗的候选患者的需求变得非常重要。在此，我们提出一种诊断算法和一种正式测量工具，即库 - 门特银屑病量表（KMPI），以帮助识别将从全身治疗中获益的患者。此外，KMPI可用于为医疗保健支付方记录并证明治疗决策的合理性。虽然进行全身治疗的决定和具体治疗方案的选择最终必须由患者和医生共同做出，但这些工具旨在提供在这些决策中具有价值的信息。
